Experience of the first adult-focussed undiagnosed disease program in Australia (AHA-UDP): solving rare and puzzling genetic disorders is ageless.
NARS
PRKACB
TOP3B
Genome sequencing
Genotype
Mosaicism
Phenotype
Rare disease
Tuberous sclerosis
Undiagnosed disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
09
08
2023
accepted:
26
07
2024
medline:
3
8
2024
pubmed:
3
8
2024
entrez:
2
8
2024
Statut:
epublish
Résumé
Significant recent efforts have facilitated increased access to clinical genetics assessment and genomic sequencing for children with rare diseases in many centres, but there remains a service gap for adults. The Austin Health Adult Undiagnosed Disease Program (AHA-UDP) was designed to complement existing UDP programs that focus on paediatric rare diseases and address an area of unmet diagnostic need for adults with undiagnosed rare conditions in Victoria, Australia. It was conducted at a large Victorian hospital to demonstrate the benefits of bringing genomic techniques currently used predominantly in a research setting into hospital clinical practice, and identify the benefits of enrolling adults with undiagnosed rare diseases into a UDP program. The main objectives were to identify the causal mutation for a variety of diseases of individuals and families enrolled, and to discover novel disease genes. Unsolved patients in whom standard genomic diagnostic techniques such as targeted gene panel, exome-wide next generation sequencing, and/or chromosomal microarray, had already been performed were recruited. Genome sequencing and enhanced genomic analysis from the research setting were applied to aid novel gene discovery. In total, 16/50 (32%) families/cases were solved. One or more candidate variants of uncertain significance were detected in 18/50 (36%) families. No candidate variants were identified in 16/50 (32%) families. Two novel disease genes (TOP3B, PRKACB) and two novel genotype-phenotype correlations (NARS, and KMT2C genes) were identified. Three out of eight patients with suspected mosaic tuberous sclerosis complex had their diagnosis confirmed which provided reproductive options for two patients. The utility of confirming diagnoses for patients with mosaic conditions (using high read depth sequencing and ddPCR) was not specifically envisaged at the onset of the project, but the flexibility to offer recruitment and analyses on an as-needed basis proved to be a strength of the AHA-UDP. AHA-UDP demonstrates the utility of a UDP approach applying genome sequencing approaches in diagnosing adults with rare diseases who have had uninformative conventional genetic analysis, informing clinical management, recurrence risk, and recommendations for relatives.
Sections du résumé
BACKGROUND
BACKGROUND
Significant recent efforts have facilitated increased access to clinical genetics assessment and genomic sequencing for children with rare diseases in many centres, but there remains a service gap for adults. The Austin Health Adult Undiagnosed Disease Program (AHA-UDP) was designed to complement existing UDP programs that focus on paediatric rare diseases and address an area of unmet diagnostic need for adults with undiagnosed rare conditions in Victoria, Australia. It was conducted at a large Victorian hospital to demonstrate the benefits of bringing genomic techniques currently used predominantly in a research setting into hospital clinical practice, and identify the benefits of enrolling adults with undiagnosed rare diseases into a UDP program. The main objectives were to identify the causal mutation for a variety of diseases of individuals and families enrolled, and to discover novel disease genes.
METHODS
METHODS
Unsolved patients in whom standard genomic diagnostic techniques such as targeted gene panel, exome-wide next generation sequencing, and/or chromosomal microarray, had already been performed were recruited. Genome sequencing and enhanced genomic analysis from the research setting were applied to aid novel gene discovery.
RESULTS
RESULTS
In total, 16/50 (32%) families/cases were solved. One or more candidate variants of uncertain significance were detected in 18/50 (36%) families. No candidate variants were identified in 16/50 (32%) families. Two novel disease genes (TOP3B, PRKACB) and two novel genotype-phenotype correlations (NARS, and KMT2C genes) were identified. Three out of eight patients with suspected mosaic tuberous sclerosis complex had their diagnosis confirmed which provided reproductive options for two patients. The utility of confirming diagnoses for patients with mosaic conditions (using high read depth sequencing and ddPCR) was not specifically envisaged at the onset of the project, but the flexibility to offer recruitment and analyses on an as-needed basis proved to be a strength of the AHA-UDP.
CONCLUSION
CONCLUSIONS
AHA-UDP demonstrates the utility of a UDP approach applying genome sequencing approaches in diagnosing adults with rare diseases who have had uninformative conventional genetic analysis, informing clinical management, recurrence risk, and recommendations for relatives.
Identifiants
pubmed: 39095811
doi: 10.1186/s13023-024-03297-5
pii: 10.1186/s13023-024-03297-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
288Informations de copyright
© 2024. The Author(s).
Références
Australian Government. National Strategic Action Plan for Rare Disease. 2020. Available from: https://www.health.gov.au/sites/default/files/documents/2020/03/national-strategic-action-plan-for-rare-diseases.pdf . Accessed 16 Aug 2022.
Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30.
pubmed: 27012247
pmcid: 4806449
doi: 10.1186/s13023-016-0409-z
Dye DE, Brameld KJ, Maxwell S, Goldblatt J, Bower C, Leonard H, et al. The impact of single gene and chromosomal disorders on hospital admissions of children and adolescents: a population-based study. Public Health Genomics. 2011;14:153–61.
pubmed: 21124008
doi: 10.1159/000321767
Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–73.
pubmed: 31527858
doi: 10.1038/s41431-019-0508-0
Stark Z, Tan TY, Chong B, Brett GR, Yap P, Walsh M, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med. 2016;18:1090–6.
pubmed: 26938784
doi: 10.1038/gim.2016.1
Tan TY, Dillon OJ, Stark Z, Schofield D, Alam K, Shrestha R, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171:855–62.
pubmed: 28759686
pmcid: 5710405
doi: 10.1001/jamapediatrics.2017.1755
Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21:2413–21.
pubmed: 31182824
pmcid: 6831729
doi: 10.1038/s41436-019-0554-6
Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312:1870–9.
pubmed: 25326635
pmcid: 4326249
doi: 10.1001/jama.2014.14601
Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312:1880–7.
pubmed: 25326637
pmcid: 4278636
doi: 10.1001/jama.2014.14604
Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18:696–704.
pubmed: 26633542
doi: 10.1038/gim.2015.148
Burdick KJ, Cogan JD, Rives LC, Robertson AK, Koziura ME, Brokamp E, et al. Limitations of exome sequencing in detecting rare and undiagnosed diseases. Am J Med Genet A. 2020;182:1400–6.
pubmed: 32190976
pmcid: 8057342
doi: 10.1002/ajmg.a.61558
Ewans LJ, Schofield D, Shrestha R, Zhu Y, Gayevskiy V, Ying K, et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. Genet Med. 2018;20:1564–74.
pubmed: 29595814
doi: 10.1038/gim.2018.39
Wright CF, McRae JF, Clayton S, Gallone G, Aitken S, FitzGerald TW, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. Genet Med. 2018;20:1216–23.
pubmed: 29323667
pmcid: 5912505
doi: 10.1038/gim.2017.246
Nambot S, Thevenon J, Kuentz P, Duffourd Y, Tisserant E, Bruel A-L, et al. Clinical whole-exome sequencing for the diagnosis of rare disorders with congenital anomalies and/or intellectual disability: substantial interest of prospective annual reanalysis. Genet Med. 2018;20:645–54.
pubmed: 29095811
doi: 10.1038/gim.2017.162
Costain G, Walker S, Marano M, Veenma D, Snell M, Curtis M, et al. Genome sequencing as a diagnostic test in children with unexplained medical complexity. JAMA Netw Open. 2020;3:e2018109.
pubmed: 32960281
pmcid: 7509619
doi: 10.1001/jamanetworkopen.2020.18109
Stark Z, Schofield D, Martyn M, Rynehart L, Shrestha R, Alam K, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21:173–80.
pubmed: 29765138
doi: 10.1038/s41436-018-0006-8
Splinter K, Adams DR, Bacino CA, Bellen HJ, Bernstein JA, Cheatle-Jarvela AM, et al. Effect of genetic diagnosis on patients with previously undiagnosed disease. N Engl J Med. 2018;379:2131–9.
pubmed: 30304647
pmcid: 6481166
doi: 10.1056/NEJMoa1714458
Gahl WA, Tifft CJ. The NIH undiagnosed diseases program: lessons learned. JAMA. 2011;305:1904–5.
pubmed: 21558523
doi: 10.1001/jama.2011.613
Gahl WA, Markello TC, Toro C, Fajardo KF, Sincan M, Gill F, et al. The NIH undiagnosed diseases program: insights into rare diseases. Genet Med. 2012;14:51–9.
pubmed: 22237431
doi: 10.1038/gim.0b013e318232a005
Taruscio D, Baynam G, Cederroth H, Groft SC, Klee EW, Kosaki K, et al. The undiagnosed diseases network international: five years and more! Mol Genet Metab. 2020;129:243–54.
pubmed: 32033911
doi: 10.1016/j.ymgme.2020.01.004
Lochmüller H, Torrent i Farnell J, Le Cam Y, Jonker AH, Lau LP, Baynam G, et al. The international rare diseases research consortium: policies and guidelines to maximize impact. Eur J Hum Genet. 2017;25:1293–302.
pubmed: 29158551
pmcid: 5865169
doi: 10.1038/s41431-017-0008-z
Cloney T, Gallacher L, Pais LS, Tan NB, Yeung A, Stark Z, et al. Lessons learnt from multifaceted diagnostic approaches to the first 150 families in Victoria’s Undiagnosed Diseases Program. J Med Genet. 2022;59:748–58.
pubmed: 34740920
doi: 10.1136/jmedgenet-2021-107902
Benson KA, White M, Allen NM, Byrne S, Carton R, Comerford E, et al. A comparison of genomic diagnostics in adults and children with epilepsy and comorbid intellectual disability. Eur J Hum Genet. 2020;28:1066–77.
pubmed: 32238909
pmcid: 7381648
doi: 10.1038/s41431-020-0610-3
Zacher P, Mayer T, Brandhoff F, Bartolomaeus T, Le Duc D, Finzel M, et al. The genetic landscape of intellectual disability and epilepsy in adults and the elderly: a systematic genetic work-up of 150 individuals. Genet Med. 2021;23:1492–7.
pubmed: 33911214
pmcid: 8354852
doi: 10.1038/s41436-021-01153-6
Walsh M, West K, Taylor JA, Thompson BA, Hopkins A, Sexton A, et al. Real world outcomes and implementation pathways of exome sequencing in an adult genetic department. Genet Med. 2022;24:1536–44.
pubmed: 35416776
doi: 10.1016/j.gim.2022.03.010
Minardi R, Licchetta L, Baroni MC, Pippucci T, Stipa C, Mostacci B, et al. Whole-exome sequencing in adult patients with developmental and epileptic encephalopathy: it is never too late. Clin Genet. 2020;98:477–85.
pubmed: 32725632
doi: 10.1111/cge.13823
Eratne D, Schneider A, Lynch E, Martyn M, Velakoulis D, Fahey M, et al. The clinical utility of exome sequencing and extended bioinformatic analyses in adolescents and adults with a broad range of neurological phenotypes: an Australian perspective. J Neurol Sci. 2021;420:117260.
pubmed: 33310205
doi: 10.1016/j.jns.2020.117260
Schuermans N, Hemelsoet D, Terryn W, Steyaert S, Van Coster R, Coucke PJ, et al. Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA). Orphanet J Rare Dis. 2022;17:210.
pubmed: 35606766
pmcid: 9128245
doi: 10.1186/s13023-022-02365-y
Salvatore M, Polizzi A, De Stefano MC, Floridia G, Baldovino S, Roccatello D, et al. Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. Ital J Pediatr. 2020;46:130.
pubmed: 32928283
pmcid: 7488856
doi: 10.1186/s13052-020-00883-8
Gahl WA, Wise AL, Ashley EA. The undiagnosed diseases network of the national institutes of health: a national extension. JAMA. 2015;314:1797–8.
pubmed: 26375289
doi: 10.1001/jama.2015.12249
López-Martín E, Martínez-Delgado B, Bermejo-Sánchez E, Alonso J, The SpainUDP Network, Posada M. SpainUDP: the Spanish undiagnosed rare diseases program. Int J Environ Res Public Health. 2018;15:1746.
pubmed: 30110963
pmcid: 6121381
doi: 10.3390/ijerph15081746
Bhatia NS, Lim JY, Bonnard C, Kuan J-L, Brett M, Wei H, et al. Singapore undiagnosed disease program: genomic analysis aids diagnosis and clinical management. Arch Dis Child. 2021;106:31–7.
pubmed: 32819910
doi: 10.1136/archdischild-2020-319180
Kim SY, Lim BC, Lee JS, Kim WJ, Kim H, Ko JM, et al. The Korean undiagnosed diseases program: lessons from a one-year pilot project. Orphanet J Rare Dis. 2019;14:68.
pubmed: 30894207
pmcid: 6427886
doi: 10.1186/s13023-019-1041-5
Adachi T, Kawamura K, Furusawa Y, Nishizaki Y, Imanishi N, Umehara S, et al. Japan’s initiative on rare and undiagnosed diseases (IRUD): towards an end to the diagnostic odyssey. Eur J Hum Genet. 2017;25:1025–8.
pubmed: 28794428
pmcid: 5558173
doi: 10.1038/ejhg.2017.106
Beaulieu CL, Majewski J, Schwartzentruber J, Samuels ME, Fernandez BA, Bernier FP, et al. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. Am J Hum Genet. 2014;94:809–17.
pubmed: 24906018
pmcid: 4121481
doi: 10.1016/j.ajhg.2014.05.003
The Deciphering Developmental Disorders (DDD) study—ProQuest. [cited 2022 Nov 29]. Available from: https://www.proquest.com/openview/c74f3e3fc754edc82de4fab719b77813/1?pq-origsite=gscholar&cbl=34809 .
Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet. 2015;385:1305–14.
pubmed: 25529582
pmcid: 4392068
doi: 10.1016/S0140-6736(14)61705-0
Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586:757–62.
pubmed: 33057194
pmcid: 7116826
doi: 10.1038/s41586-020-2832-5
Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–8.
doi: 10.1038/nature21062
Boycott KM, Hartley T, Kernohan KD, Dyment DA, Howley H, Innes AM, et al. Care4Rare Canada: outcomes from a decade of network science for rare disease gene discovery. Am J Hum Genet. 2022;109:1947–59.
pubmed: 36332610
pmcid: 9674964
doi: 10.1016/j.ajhg.2022.10.002
Dolzhenko E, Bennett MF, Richmond PA, Trost B, Chen S, van Vugt JJFA, et al. ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data. Genome Biol. 2020;21:102.
pubmed: 32345345
pmcid: 7187524
doi: 10.1186/s13059-020-02017-z
Tankard RM, Bennett MF, Degorski P, Delatycki MB, Lockhart PJ, Bahlo M. Detecting expansions of tandem repeats in cohorts sequenced with short-read sequencing data. Am J Hum Genet. 2018;103:858–73.
pubmed: 30503517
pmcid: 6288141
doi: 10.1016/j.ajhg.2018.10.015
Munro JE, Dunwoodie SL, Giannoulatou E. SVPV: a structural variant prediction viewer for paired-end sequencing datasets. Bioinformatics. 2017;33:2032–3.
pubmed: 28334120
doi: 10.1093/bioinformatics/btx117
Girdea M, Dumitriu S, Fiume M, Bowdin S, Boycott KM, Chénier S, et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat. 2013;34:1057–65.
pubmed: 23636887
doi: 10.1002/humu.22347
GATK. [cited 2022 Aug 25]. Available from: https://gatk.broadinstitute.org/hc/en-us .
Van der Auwera GA, O’Connor BD. Genomics in the cloud: using Docker, GATK, and WDL in Terra. 1st ed. Sebastopol: O’Reilly Media; 2020.
Abyzov A, Urban AE, Snyder M, Gerstein M. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. 2011;21:974–84.
pubmed: 21324876
pmcid: 3106330
doi: 10.1101/gr.114876.110
Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220–2.
pubmed: 26647377
doi: 10.1093/bioinformatics/btv710
Pedersen B. Smoove: structural variant calling and genotyping with existing tools, but, smoothly. [cited 2022 Aug 25]. Available from: https://hpc.nih.gov/apps/smoove.html .
Dolzhenko E, Deshpande V, Schlesinger F, Krusche P, Petrovski R, Chen S, et al. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35:4754–6.
pubmed: 31134279
pmcid: 6853681
doi: 10.1093/bioinformatics/btz431
Ye Z, Lin S, Zhao X, Bennet MF, Brown NJ, Wallis M, et al. Mosaicism in tuberous sclerosis complex—lowering the threshold for clinical reporting. Hum Mutat. 2022;43(12):1956–69.
pubmed: 36030538
doi: 10.1002/humu.24454
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.
pubmed: 25741868
pmcid: 4544753
doi: 10.1038/gim.2015.30
Rafehi H, Szmulewicz DJ, Pope K, Wallis M, Christodoulou J, White SM, et al. Rapid diagnosis of spinocerebellar ataxia 36 in a three-generation family using short-read whole-genome sequencing data. Mov Disord. 2020;35:1675–9.
pubmed: 32407596
doi: 10.1002/mds.28105
Zhang T, Wallis M, Petrovic V, Challis J, Kalitsis P, Hudson DF. Loss of TOP3B leads to increased R-loop formation and genome instability. Open Biol. 2019;9:190222.
pubmed: 31795919
pmcid: 6936252
doi: 10.1098/rsob.190222
Palencia-Campos A, Aoto PC, Machal EMF, Rivera-Barahona A, Soto-Bielicka P, Bertinetti D, et al. Germline and mosaic variants in PRKACA and PRKACB cause a multiple congenital malformation syndrome. Am J Hum Genet. 2020;107:977–88.
pubmed: 33058759
pmcid: 7675002
doi: 10.1016/j.ajhg.2020.09.005
Beijer D, Marte S, Li JC, De Ridder W, Chen JZ, Tadenev ALD, et al. Dominant NARS1 mutations causing axonal Charcot–Marie–Tooth disease expand NARS1-associated diseases. Brain Commun. 2024;6(2):fcae070. https://doi.org/10.1093/braincomms/fcae070 .
doi: 10.1093/braincomms/fcae070
pubmed: 38495304
Kleefstra T, Kramer JM, Neveling K, Willemsen MH, Koemans TS, Vissers LELM, et al. Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability. Am J Hum Genet. 2012;91:73–82.
pubmed: 22726846
pmcid: 3397275
doi: 10.1016/j.ajhg.2012.05.003
Koemans TS, Kleefstra T, Chubak MC, Stone MH, Reijnders MRF, de Munnik S, et al. Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder. PLoS Genet. 2017;13:e1006864.
pubmed: 29069077
pmcid: 5656305
doi: 10.1371/journal.pgen.1006864
Li W-D, Li Q-R, Xu S-N, Wei F-J, Ye Z-J, Cheng J-K, et al. Exome sequencing identifies an MLL3 gene germ line mutation in a pedigree of colorectal cancer and acute myeloid leukemia. Blood. 2013;121:1478–9.
pubmed: 23429989
doi: 10.1182/blood-2012-12-470559
Sasaki MM, Skol AD, Bao R, Rhodes LV, Chambers R, Vokes EE, et al. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2015;24:1222–8.
doi: 10.1158/1055-9965.EPI-15-0275
Yan L, Zhang Y, Ding B, Zhou H, Yao W, Xu H. Genetic alteration of histone lysine methyltransferases and their significance in renal cell carcinoma. PeerJ. 2019;7:e6396.
pubmed: 30755832
pmcid: 6368835
doi: 10.7717/peerj.6396
Treichel AM, Hamieh L, Nathan NR, Tyburczy ME, Wang J, Oyerinde O, et al. Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genet Med. 2019;21:2594–604.
pubmed: 31114024
pmcid: 7875483
doi: 10.1038/s41436-019-0520-3
Giannikou K, Lasseter KD, Grevelink JM, Tyburczy ME, Dies KA, Zhu Z, et al. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission. Genet Med. 2019;21:2639–43.
pubmed: 31160751
doi: 10.1038/s41436-019-0562-6
Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews®. Seattle: University of Washington, Seattle; 1993 [cited 2022 Nov 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1220/ .
Jones AC, Shyamsundar MM, Thomas MW, Maynard J, Idziaszczyk S, Tomkins S, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64:1305–15.
pubmed: 10205261
pmcid: 1377866
doi: 10.1086/302381
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68:64–80.
pubmed: 11112665
doi: 10.1086/316951
Au K-S, Williams AT, Gambello MJ, Northrup H. Molecular genetic basis of tuberous sclerosis complex: from bench to bedside. J Child Neurol. 2004;19:699–709.
pubmed: 15563017
doi: 10.1177/08830738040190091101
Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13:731–41.
pubmed: 15798777
doi: 10.1038/sj.ejhg.5201402
Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. 2007;9:88–100.
pubmed: 17304050
doi: 10.1097/GIM.0b013e31803068c7
Tyburczy ME, Dies KA, Glass J, Camposano S, Chekaluk Y, Thorner AR, et al. Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing. PLoS Genet. 2015;11:e1005637.
pubmed: 26540169
pmcid: 4634999
doi: 10.1371/journal.pgen.1005637
Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43:D789-798.
pubmed: 25428349
doi: 10.1093/nar/gku1205
Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019;51:1560–5.
pubmed: 31676867
doi: 10.1038/s41588-019-0528-2
Rafehi H, Szmulewicz DJ, Bennett MF, Sobreira NLM, Pope K, Smith KR, et al. Bioinformatics-based identification of expanded repeats: A non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am J Hum Genet. 2019;105:151–65.
pubmed: 31230722
pmcid: 6612533
doi: 10.1016/j.ajhg.2019.05.016
Rafehi H, Read J, Szmulewicz DJ, Davies KC, Snell P, Fearnley LG, et al. An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA50/ATX-FGF14. Am J Hum Genet. 2023;110:105–19.
pubmed: 36493768
doi: 10.1016/j.ajhg.2022.11.015
Mellis R, Oprych K, Scotchman E, Hill M, Chitty LS. Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: a systematic review and meta-analysis. Prenat Diagn. 2022;42:662–85.
pubmed: 35170059
pmcid: 9325531
doi: 10.1002/pd.6115
Gorini F, Coi A, Mezzasalma L, Baldacci S, Pierini A, Santoro M. Survival of patients with rare diseases: a population-based study in Tuscany (Italy). Orphanet J Rare Dis. 2021;16:275.
pubmed: 34127030
pmcid: 8201697
doi: 10.1186/s13023-021-01907-0
Carver T, Hartley S, Lee A, Cunningham AP, Archer S, de Villiers CB, et al. CanRisk Tool—A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. Cancer Epidemiol Biomark Prev. 2021;30:469–73.
doi: 10.1158/1055-9965.EPI-20-1319
Spillmann RC, McConkie-Rosell A, Pena L, Jiang Y-H, Adams CJ, Adams DR, et al. A window into living with an undiagnosed disease: illness narratives from the Undiagnosed Diseases Network. Orphanet J Rare Dis. 2017;12:71.
pubmed: 28416019
pmcid: 5392939
doi: 10.1186/s13023-017-0623-3
Sachdev R, Field M, Baynam GS, Beilby J, Berarducci M, Berman Y, et al. Paediatric genomic testing: navigating medicare rebatable genomic testing. J Paediatr Child Health. 2021;57:477–83.
pubmed: 33566436
pmcid: 8049061
doi: 10.1111/jpc.15382
Schofield D, Rynehart L, Shresthra R, White SM, Stark Z. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. Genet Med. 2019;21:2586–93.
pubmed: 31110331
doi: 10.1038/s41436-019-0534-x
The Australian Undiagnosed Diseases Network. Australian Genomics. [cited 2022 Nov 23]. Available from: https://www.australiangenomics.org.au/research/the-australian-undiagnosed-diseases-network/ .
Broad Institute [Internet]. Broad Institute. [cited 2022 Aug 25]. Available from: https://www.broadinstitute.org/home .
Pais LS, Snow H, Weisburd B, Zhang S, Baxter SM, DiTroia S, et al. seqr: a web-based analysis and collaboration tool for rare disease genomics. Hum Mutat. 2022;43:698–707.
pubmed: 35266241
pmcid: 9903206